Generic Azmiro Availability

Last updated on May 7, 2025.

Azmiro is a brand name of testosterone, approved by the FDA in the following formulation(s):

AZMIRO (testosterone cypionate - solution;intramuscular)

• Manufacturer: AZURITY
  Approval date: June 2, 2022
  Strength(s): 200MG/ML (200MG/ML) ^[RLD]

Is there a generic version of Azmiro available?

No. There is currently no therapeutically equivalent version of Azmiro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azmiro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Pharmaceutical compositions of testosterone
  Patent 11,311,554
  Issued: April 26, 2022
  Inventor(s): Soni; Umangi K. et al.
  Assignee(s): SLAYBACK PHARMA LLC (Princeton, NJ)
  

  The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.

  Patent expiration dates:

  • March 25, 2039
    
    ✓ 
    Drug product
• Pharmaceutical compositions of testosterone
  Patent 11,642,355
  Issued: May 9, 2023
  Inventor(s): Soni; Umangi K. et al.
  Assignee(s): SLAYBACK PHARMA LLC (Princeton, NJ)
  

  The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, as well as methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.

  Patent expiration dates:

  • March 25, 2039
    
    ✓ 
    Drug product
• Pharmaceutical compositions of testosterone
  Patent 12,138,271
  Issued: November 12, 2024
  Inventor(s): Soni; Umangi K. et al.
  Assignee(s): SLAYBACK PHARMA LLC (Princeton, NJ)
  

  Stable pharmaceutical compositions are provided, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.

  Patent expiration dates:

  • March 25, 2039
    
    ✓ 
    Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer